Clinical trials: Immunocompromised
Rabies Exposure, Immunocompromised
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients…
- Conditions
- Rabies Exposure, Immunocompromised, Chronic Disease
- Trial name
- NCT07120464
- Testing
- Observation Only
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Haematological Disorders
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
The UK Medicine and Healthcare products Regulatory Agency (MHRA) granted temporary authorisation to three Covid-19 vaccines in December 2020 and January 2021.
- Conditions
- Covid19, Haematological Disorders, Immune Suppression
- Trial name
- COVAC-IC (NCT04805216)
- Testing
- Blood test
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Pharmacokinetics
A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole.
- Trial name
- NCT00556998
- Testing
- Voriconazole
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
- Trial name
- NCT07092865
- Testing
- Adjuvanted RSVPreF3 vaccine
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 168 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Inflammatory Bowel Diseases
Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster
Inflammatory bowel disease (IBD) patients under the age of 50 can have a greater risk than the general population above age 50. IBD patient are commonly treated with immunosuppression that increases the risk for Herpes Zoster.
- Conditions
- Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT03553472
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
COVID-19, SARS-CoV-2
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of COVID-19 in immunocompromised adults.
- Trial name
- VICTORIA (NCT05057897)
- Testing
- AZD1222
- Where
- 4 sites in Thailand, Ukraine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cancer
Booster Dose Trial
The goal of this study is to assess the safety and effectiveness of COVID vaccine booster doses in patients with cancer who have not developed an antibody after the U.S.
- Trial name
- NCT05016622
- Testing
- BNT162b2 vaccine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Montefiore Medical Center
Tuberculosis, Monitoring, Immunologic
T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals
Until recently, the tuberculin skin test (TST) was the only available diagnostic assay for detection of latent infection with M. tuberculosis (LTBI).
- Trial name
- TBNET-TIPS (NCT00707317)
- Where
- 21 sites in Australia, Bulgaria and 12 more
- Volunteers
- 1,843 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Network European Trialsgroup
Cryptosporidium Infection
The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
This study aims to: 1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2.
- Trial name
- NCT07388615
- Testing
- Echinacea Extract
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Al-Azhar University
HIV-1-infection, Cancer
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy…
- Conditions
- HIV-1-infection, Cancer, Primary Immune Deficiency Disorder, Immunosuppression Disorders
- Trial name
- CORIA (NCT04354818)
- Where
- 11 sites in Australia
- Volunteers
- 27 people
- Sponsor
- Kirby Institute
BK Polyomavirus
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK…
- Trial name
- BK-CTLs (NCT04293042)
- Testing
- BK-virus specific CTLs
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Philadelphia
Candidiasis, Esophageal, HIV Infections
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.
- Trial name
- NCT00002132
- Testing
- Itraconazole, Fluconazole
- Where
- 18 sites in United States
- Sponsor
- Janssen Pharmaceuticals
Invasive Infection, Diabetic Foot
Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.
Group B Streptococcus (GBS) infection is a potential aetiology of meningitis and septicemia in neonates, pregnant women and non-pregnant adults.
- Conditions
- Invasive Infection, Diabetic Foot, Immunocompromised Patients, Group B Streptococcal Infections
- Trial name
- NCT05726006
- Testing
- No Intervention in This study
- Where
- Malaysia
- Volunteers
- 133 people
- Sponsor
- Universiti Putra Malaysia
Anogenital Herpes, COVID-19
Viral Infections in Healthy and Immunocompromised Hosts
Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Trial name
- NCT01306084
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic…
- Trial name
- NCT02058589
- Testing
- Herpes Zoster vaccine GSK1437173A
- Where
- 34 sites in Belgium, Canada and 7 more
- Volunteers
- 265 people
- Sponsor
- GlaxoSmithKline
Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT)
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are…
- Conditions
- Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
- Trial name
- ATLANTIC (NCT04691622)
- Testing
- Norovirus -specific T-cell (NST) therapy
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Children's National Research Institute
Respiratory Syncytial Virus Infection
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.
- Trial name
- NCT01466062
- Testing
- Palivizumab
- Where
- 6 sites in Japan
- Volunteers
- 28 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Tuberculosis
Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations
The tuberculin skin test (TST) has been the gold standard for diagnosing latent tuberculosis for almost 100 years. While this test performs reasonably well in healthy, non-bacille Calmette-Guerin (BCG) vaccinated populations, it…
- Trial name
- NCT00134342
- Testing
- T-SPOT TB ELISPOT test
- Where
- 2 sites in Canada
- Volunteers
- 203 people
- Sponsor
- University Health Network, Toronto
Severe Acute Respiratory Infection, Community-acquired Pneumonia
mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients
Severe Community-acquired pneumonia (SCAP) is a leading global infectious cause of intensive care unit (ICU) admission (approximately 20%-30%), and the primary reason of mortality and morbidity in immunocompromised patients.
- Conditions
- Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia
- Trial name
- MATESHIP (NCT05290454)
- Testing
- mNGS-guided treatment
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Qilu Hospital of Shandong University